CH
Therapeutic Areas
Wayfinder Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| c-MYC Program | Oncology | Discovery/Hit-to-Lead |
| Undisclosed Program | Neurodegeneration | Target ID/Discovery |
| Drug | Indication | Phase |
|---|---|---|
| c-MYC Program | Oncology | Discovery/Hit-to-Lead |
| Undisclosed Program | Neurodegeneration | Target ID/Discovery |